Companies/Opus Genetics, Inc.

Company profile

Opus Genetics, Inc.

NASDAQ: IRD · Healthcare · Biotechnology

PublicHQ Durham, MICIK 0001228627Reports USD

#585 of 1,394 Healthcare companies by revenue71st-percentile growth

EA Score

38D

FH 31DQ 47GM 32SS 54

v0.1 · 65/100 weight · provisional

↑ market scale, revenue growth (YoY) · ↓ growth stability, return on equity

Methodology →

Revenue TTM

$12.0M

Rev growth YoY (TTM)

-12.2%

Net income (FY)

-$49.6M

Employees

Market cap

$349.3M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$14.2M$14.2M2025

Net income-$49.6M-$49.6M2025

Operating income-$38.6M-$38.6M2025

Total assets$50.2M$50.2M2025

Liabilities$34.9M$34.9M2025

Equity$15.3M$15.3M2025

Revenue trend

FY2013 – FY2025 · USD

FY13

$3.0M

FY19

FY21

$589.0k

FY21

$39.9M

FY22

$19.0M

FY23

$11.0M

FY24

$14.2M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Opus Genetics, Inc. booked $14.2M in FY2025 revenue, growing 29% year over year — faster than most Healthcare companies we track, at a -349.3% net margin.

Peers · Healthcare

Enanta Pharmaceuticals, Inc.55C Benitec Biopharma Inc.47D Ovid Therapeutics Inc.49D C4 Therapeutics, Inc.50D

Key facts

CEOGeorge Magrath

SectorHealthcare

IndustryBiotechnology

HeadquartersDurham, MI

ExchangeNASDAQ: IRD

Employees18

IPO date2015-01-19

Latest filings

8-K2026-06-16 8-K2026-06-16 10-Q2026-05-12 8-K2026-05-12 8-K2026-04-24 8-K2026-04-22 8-K2026-04-07 8-K2026-04-07

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.